Detail akcie Connect Biophar Rg online

Business Summary: Connect Biopharma Holdings Limited is a global clinical-stage biopharmaceutical company. The Company is focused on advancing rademikibart, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4R?) antibody, to transform acute and chronic care in asthma and chronic obstructive pulmonary disease (COPD). Its lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4R?) in development for the treatment of atopic dermatitis (AD) and asthma. As an inhibitor of IL-4R?, rademikibart blocks inflammatory signaling by both IL-4 and IL-13. The Company has completed a global Phase II trial (CBP-201-WW001) of rademikibart in adult patients with moderate-to-severe AD.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Connect Biopharma Holdings Ltd (ADR) revenues decreased 95% to $64K. Net loss increased 87% to $40.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Treatment of respiratory diseases segment loss increase of 61% to $42.5M.